Kanvas makes the microbiome druggable — and the impli­ca­tions are massive

Ever since the genomics revolution revealed how reliant the human organism is on its microscopic microbial cohabitants, the microbiome has been medicine’s most elusive frontier, promising better health if only we could untangle the trillions of inter­ac­tions that influence nearly every facet of our physiology. But until now, effective medicines that harness the microbiome have been rare. Because of the diversity of microbial species and the complexity of host-to-microbe inter­ac­tions, as well as the lack of a reliable, easily manu­fac­tured drug modality (the package that delivers a medicine’s therapeutic effect), the microbiome has been hard to treat, despite its importance to functions like immune response. Microbiome science has disap­pointed patients, doctors, founders, and investors. 

That’s why DCVC is so excited about the cascade of recent devel­op­ments at Kanvas Biosciences, which is moving the field beyond descriptive profiling of the microbiome to translating compre­hen­sive biochemical insights into clinically useful products. In the past few weeks, the Princeton-based spatial biology company has kicked off a Phase 1 clinical trial for its first drug candidate, secured significant new backing from the Gates Foundation (closing a $48M Series A financing, bringing Kanvas’s total funding to $78 million), and bolstered its scientific leadership by adding one of the most respected names in bioengi­neering to its board.

Clinical milestone

The most significant milestone in Kanvas’s evolution is the dosing of the first patients in a Phase I clinical trial for KAN-004. This live biother­a­peutic product (LBP), resembling an ordinary pill, treats the colitis that many cancer patients develop after receiving immune checkpoint inhibitors (ICIs), allowing them to remain on the life-saving therapy longer. 

Later this year, Kanvas will also begin trials of a potential blockbuster immuno-oncology drug, KAN-001, designed to directly improve response rates to ICIs in patients with solid organ cancers. While ICIs like Keytruda — the world’s top-selling drug with $31.7 billion in 2025 revenue — are miraculous medicines that have revo­lu­tion­ized oncology, providing life-changing cures of the hardest-to-treat cancers, only 20 to 40 percent of patients currently respond to such therapies. Kanvas hopes that KAN-001 might double response rates to ICIs, while simul­ta­ne­ously reducing adverse events. 

Research has shown that so-called ​“superdonors” — individuals with excep­tion­ally high microbiome diversity, and who possess specific strains of microbes — respond better to immunotherapy. In collab­o­ra­tion with the University of Texas MD Anderson Cancer Center, Kanvas is using its platforms to isolate, optimize, and synthesize the specific microbial strains active in these high-responding patients, and then manufacture them as LBPs. By admin­is­tering the strains as a stan­dard­ized oral drug, Kanvas aims to turn non-responders into responders, and treat patients at scale in a way that fecal transplants (the current modality for microbiome medicines) simply cannot.

The general clinical approach to engineering the microbiome to treat cancer has already been tried and tested, but with a much less attractive medicine. In a recent fecal microbial transfer trial for refractory cancers at MD Anderson, fecal material from the donor who provided the microbial strains in KAN-001 were delivered to partic­i­pants. Results were promising, including for one colorectal patient who was cancer free for more than two years. 

Global impact

Kanvas’ ambitions extend beyond oncology. The company recently announced a new investment from the Gates Foundation to develop the world’s first fully synthetic microbiome replacement for maternal envi­ron­mental enteric dysfunction (EED), a debil­i­tating intestinal condition, better known as tropical sprue, affecting approx­i­mately over 150 million people worldwide, primarily in poor countries in Southern Asia and Sub-Saharan Africa. It causes chronic gut inflam­ma­tion and nutrient malab­sorp­tion, leading to stunted growth and inter­gen­er­a­tional health impacts.

By treating expectant mothers with a precision-engineered consortia of native microbial strains, Kanvas aims to improve the health of both mothers and newborns simul­ta­ne­ously. The collab­o­ra­tion with the Gates Foundation highlights the power of the Kanvas platforms. The same engineering mindset used to treat cancer will be deployed to solve one of the world’s most persistent global health challenges, a break­through especially pleasing to Kanvas cofounder and CEO Matt Cheng, who is an infectious disease doctor. ​“As a physician, I spent years watching patients suffer from conditions I couldn’t treat. To suggest that it is a once-in-a-lifetime opportunity to help so many people would be an under­state­ment,” Cheng adds. ​“To tackle a problem of this magnitude is both a privilege and a respon­si­bility we carry with conviction.”

Resources and talent

Kanvas’s momentum is funded by a fresh $48 million Series A funding round, which DCVC is thrilled to be co-leading (we’ve backed the company since its inception in 2021). The capital will allow Kanvas to continue oper­a­tional­izing its full-stack strategy, which includes the opening of a state-of-the-art GMP manu­fac­turing suite and an advanced anaerobic fermen­ta­tion facility in South San Francisco. 

Unlike many biotech firms that outsource production, Kanvas built its own fully anaerobic GMP capa­bil­i­ties to manufacture complex microbial consortia — some containing hundreds of unique members — consis­tently and at scale, supporting both its own programs and paying customers. This vertical integration is powered by the company’s proprietary microbiome atlas and the Kanvas Spectral Lightsheet, a proprietary high-resolution microscope that generates unprece­dented amounts of spatial biology data to train Kanvas’s AI drug-discovery platform.

Finally, Kanvas is furthering its strategic leadership with the appointment of Stephen Quake to its Board of Directors. Quake pioneered the development of microflu­idics and its application to DNA sequencing and diagnostics. As the Lee Otterson Professor of Bioengi­neering and Applied Physics at Stanford University and the former Chief Science Advisor for the Chan Zuckerberg Initiative, Dr. Quake brings unrivaled expertise in scaling trans­for­ma­tive biological tech­nolo­gies, and his addition is a true sign of confidence in Kanvas’s ability to unlock the microbiome’s vast potential. 

With clinical trials under way, a powerful new global health initiative, and the infra­struc­ture to manufacture its discoveries, Kanvas Biosciences is not just dreaming of a future where a profound under­standing of the microbiome is turned into products that promote our health, it is engineering it today.